• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
L-ascorbic acid: A true substrate for HIF prolyl hydroxylase?L-抗坏血酸:真的是 HIF 脯氨酰羟化酶的底物吗?
Biochimie. 2018 Apr;147:46-54. doi: 10.1016/j.biochi.2017.12.011. Epub 2017 Dec 28.
2
Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.缺氧诱导因子脯氨酰羟化酶抑制剂开发的最新进展及其治疗意义
Molecules. 2015 Nov 19;20(11):20551-68. doi: 10.3390/molecules201119717.
3
Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.莫立司他抑制脯氨酰羟化酶结构基础。
ChemMedChem. 2021 Jul 6;16(13):2082-2088. doi: 10.1002/cmdc.202100133. Epub 2021 Apr 9.
4
Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.补体 C1q 由胶原蛋白脯氨酰 4 羟化酶羟化,并且对稳定缺氧诱导因子的脯氨酰羟化酶结构域抑制剂的非靶标抑制敏感。
Kidney Int. 2017 Oct;92(4):900-908. doi: 10.1016/j.kint.2017.03.008. Epub 2017 May 12.
5
A Fluorescent Benzo[g]isoquinoline-Based HIF Prolyl Hydroxylase Inhibitor for Cellular Imaging.一种用于细胞成像的基于荧光苯并[g]异喹啉的 HIF 脯氨酰羟化酶抑制剂。
ChemMedChem. 2019 Jan 8;14(1):94-99. doi: 10.1002/cmdc.201800483. Epub 2018 Dec 21.
6
Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells.抗坏血酸和抗坏血酸-2-磷酸酯可降低人黑色素瘤细胞的缺氧诱导因子(HIF)活性及恶性特性。
BMC Cancer. 2015 Nov 7;15:867. doi: 10.1186/s12885-015-1878-5.
7
N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant.N-(2-巯基丙酰基)-甘氨酸,一种可扩散的抗氧化剂,通过抑制 HIF-1 脯氨酰羟化酶-2 来激活 HIF-1:抗氧化剂在改善大鼠结肠炎中的作用机制。
Biochem Biophys Res Commun. 2014 Jan 17;443(3):1008-13. doi: 10.1016/j.bbrc.2013.12.081. Epub 2013 Dec 19.
8
Structure-Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors.缺氧诱导因子脯氨酰羟化酶抑制剂的构效关系及转录组分析
Antioxidants (Basel). 2022 Jan 24;11(2):220. doi: 10.3390/antiox11020220.
9
Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells.脯氨酰羟化酶 2:抑制肿瘤细胞缺氧诱导的细胞代谢的有前景的靶点。
Drug Discov Today. 2018 Nov;23(11):1873-1882. doi: 10.1016/j.drudis.2018.05.016. Epub 2018 May 14.
10
Prolyl hydroxylase inhibitors protect from the bone loss in ovariectomy rats by increasing bone vascularity.脯氨酰羟化酶抑制剂通过增加骨血管生成来防止去卵巢大鼠的骨丢失。
Cell Biochem Biophys. 2014 May;69(1):141-9. doi: 10.1007/s12013-013-9780-8.

引用本文的文献

1
The potentially therapeutic effects of ascorbic acid in different cell line in attempt to reduce the risk of radiation therapy.为降低放射治疗风险,抗坏血酸在不同细胞系中的潜在治疗作用。
Sci Rep. 2025 Apr 29;15(1):15077. doi: 10.1038/s41598-025-96697-x.
2
Biochemical investigations using mass spectrometry to monitor JMJD6-catalysed hydroxylation of multi-lysine containing bromodomain-derived substrates.使用质谱法进行生化研究,以监测JMJD6催化的含多赖氨酸的溴结构域衍生底物的羟基化反应。
RSC Chem Biol. 2025 Feb 24;6(4):642-656. doi: 10.1039/d4cb00311j. eCollection 2025 Apr 2.
3
Exploring the Ascorbate Requirement of the 2-Oxoglutarate-Dependent Dioxygenases.探索2-酮戊二酸依赖性双加氧酶的抗坏血酸需求
J Med Chem. 2025 Feb 13;68(3):2219-2237. doi: 10.1021/acs.jmedchem.4c02342. Epub 2025 Jan 30.
4
Integrated transcriptomic analysis and machine learning for characterizing diagnostic biomarkers and immune cell infiltration in fetal growth restriction.整合转录组分析和机器学习用于鉴定胎儿生长受限的诊断生物标志物和免疫细胞浸润。
Front Immunol. 2024 Sep 4;15:1381795. doi: 10.3389/fimmu.2024.1381795. eCollection 2024.
5
Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma.选择性抑制HDAC6对肾细胞癌具有抗癌作用的潜力。
J Pers Med. 2024 Jun 30;14(7):704. doi: 10.3390/jpm14070704.
6
Unraveling the 2,3-diketo-L-gulonic acid-dependent and -independent impacts of L-ascorbic acid on somatic cell reprogramming.解析L-抗坏血酸对体细胞重编程的2,3-二酮-L-古洛糖酸依赖性和非依赖性影响。
Cell Biosci. 2023 Nov 30;13(1):218. doi: 10.1186/s13578-023-01160-x.
7
Structure and Function of TET Enzymes.TET 酶的结构与功能。
Adv Exp Med Biol. 2022;1389:239-267. doi: 10.1007/978-3-031-11454-0_10.
8
High-Dose Vitamin C for Cancer Therapy.大剂量维生素C用于癌症治疗
Pharmaceuticals (Basel). 2022 Jun 3;15(6):711. doi: 10.3390/ph15060711.
9
Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2.人参皂苷 Rh2 增强多柔比星抗肿瘤活性的可能机制。
Molecules. 2022 Jan 19;27(3):628. doi: 10.3390/molecules27030628.
10
Vitamin C Deficiency in the Young Brain-Findings from Experimental Animal Models.儿童大脑维生素 C 缺乏症——来自实验动物模型的研究发现。
Nutrients. 2021 May 15;13(5):1685. doi: 10.3390/nu13051685.

本文引用的文献

1
Human Collagen Prolyl 4-Hydroxylase Is Activated by Ligands for Its Iron Center.人胶原蛋白脯氨酰4-羟化酶被其铁中心的配体激活。
Biochemistry. 2016 Jun 14;55(23):3224-33. doi: 10.1021/acs.biochem.6b00251. Epub 2016 May 31.
2
Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models.在几种啮齿动物模型中,对氧感应脯氨酰羟化酶进行治疗性靶向可消除ATF4依赖性神经元死亡,并改善脑出血后的预后。
Sci Transl Med. 2016 Mar 2;8(328):328ra29. doi: 10.1126/scitranslmed.aac6008.
3
A novel effect of DMOG on cell metabolism: direct inhibition of mitochondrial function precedes HIF target gene expression.二甲基乙二酰甘氨酸(DMOG)对细胞代谢的一种新作用:在低氧诱导因子(HIF)靶基因表达之前直接抑制线粒体功能。
Biochim Biophys Acta. 2015 Oct;1847(10):1254-66. doi: 10.1016/j.bbabio.2015.06.016. Epub 2015 Jul 2.
4
Regulation of the Epigenome by Vitamin C.维生素C对表观基因组的调控
Annu Rev Nutr. 2015;35:545-64. doi: 10.1146/annurev-nutr-071714-034228. Epub 2015 May 6.
5
Ascorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression.抗坏血酸作为铁依赖型和 2-氧代戊二酸依赖型双加氧酶的辅助因子:在肿瘤生长和进展中的生理活性。
Front Oncol. 2014 Dec 10;4:359. doi: 10.3389/fonc.2014.00359. eCollection 2014.
6
Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue.抗坏血酸通过正常组织和肿瘤组织扩散的药代动力学模型。
Free Radic Biol Med. 2014 Dec;77:340-52. doi: 10.1016/j.freeradbiomed.2014.09.023. Epub 2014 Sep 30.
7
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.高剂量静脉注射抗坏血酸增强卵巢癌的化疗敏感性并降低化疗毒性。
Sci Transl Med. 2014 Feb 5;6(222):222ra18. doi: 10.1126/scitranslmed.3007154.
8
Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response.细胞内抗坏血酸增强低氧诱导因子 (HIF)-羟化酶活性,并优先抑制 HIF-1 转录反应。
Free Radic Biol Med. 2014 Apr;69:308-17. doi: 10.1016/j.freeradbiomed.2014.01.033. Epub 2014 Feb 2.
9
Deal watch: AstraZeneca bets on FibroGen's anaemia drug.交易观察:阿斯利康押注于菲布罗根公司的贫血药物。
Nat Rev Drug Discov. 2013 Oct;12(10):730. doi: 10.1038/nrd4135.
10
Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals.抗坏血酸增强 Tet 介导的 5-甲基胞嘧啶氧化并促进哺乳动物的 DNA 去甲基化。
J Am Chem Soc. 2013 Jul 17;135(28):10396-403. doi: 10.1021/ja4028346. Epub 2013 Jul 1.

L-抗坏血酸:真的是 HIF 脯氨酰羟化酶的底物吗?

L-ascorbic acid: A true substrate for HIF prolyl hydroxylase?

机构信息

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117997, Moscow, Russian Federation.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117997, Moscow, Russian Federation.

出版信息

Biochimie. 2018 Apr;147:46-54. doi: 10.1016/j.biochi.2017.12.011. Epub 2017 Dec 28.

DOI:10.1016/j.biochi.2017.12.011
PMID:29289682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6460286/
Abstract

L-Ascorbate (L-Asc), but not D-isoascorbate (D-Asc) and N-acetylcysteine (NAC) suppress HIF1 ODD-luc reporter activation induced by various inhibitors of HIF prolyl hydroxylase (PHD). The efficiency of suppression by L-Asc was sensitive to the nature of HIF PHD inhibitor chosen for reporter activation. In particular, the inhibitors developed to compete with alpha-ketoglutarate (αKG), were less sensitive to suppression by the physiological range of L-Asc (40-100 μM) than those having a strong iron chelation motif. Challenging those HIF activators in the reporter system with D-Asc demonstrated that the D-isomer, despite exhibiting the same reducing potency with respect to ferric iron, had almost no effect compared to L-Asc. Similarly, no effect on reporter activation was observed with cell-permeable reducing agent NAC up to 1 mM. Docking of L-Asc and D-Asc acid into the HIF PHD2 crystal structure showed interference of Tyr310 with respect to D-Asc. This suggests that L-Asc is not merely a reducing agent preventing enzyme inactivation. Rather, the overall results identify L-Asc as a co-substrate of HIF PHD that may compete for the binding site of αKG in the enzyme active center. This conclusion is in agreement with the results obtained recently in cell-based systems for TET enzymes and jumonji histone demethylases, where L-Asc has been proposed to act as a co-substrate and not as a reducing agent preventing enzyme inactivation.

摘要

L-抗坏血酸(L-Asc),而不是 D-异抗坏血酸(D-Asc)和 N-乙酰半胱氨酸(NAC),可抑制各种脯氨酰羟化酶(PHD)抑制剂诱导的 HIF1 ODD-luc 报告基因激活。L-Asc 的抑制效率对所选报告基因激活的 HIF PHD 抑制剂的性质敏感。特别是,与α-酮戊二酸(αKG)竞争的抑制剂,对生理范围内的 L-Asc(40-100μM)的抑制作用不如具有强铁螯合基序的抑制剂敏感。在报告基因系统中用 D-Asc 挑战那些 HIF 激活剂表明,尽管 D-异构体在还原高铁方面表现出相同的效力,但与 L-Asc 相比几乎没有效果。同样,细胞通透性还原剂 NAC 即使高达 1mM,也没有观察到对报告基因激活的影响。将 L-Asc 和 D-Asc 酸对接进入 HIF PHD2 晶体结构表明,D-Asc 对 Tyr310 存在干扰。这表明 L-Asc 不仅仅是一种还原剂,可防止酶失活。相反,总体结果表明 L-Asc 是 HIF PHD 的共底物,可能与酶活性中心的 αKG 结合位点竞争。这一结论与最近在基于细胞的 TET 酶和 jumonji 组蛋白去甲基酶系统中获得的结果一致,其中提出 L-Asc 作为共底物而不是还原剂,可防止酶失活。